BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was ...
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved ...
Ex-Platinum Games employee Hideki Kamiya has seemingly joined the debate surrounding Assassin's Creed Shadows.
Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan. “There is significant need for new treatment options for ATTR-CM, a progressive ...
JAMA Cardiol. 2024 Dec 4:e244102. Beyonttra is an orally administered near-complete (≥90%) stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin ...
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated In the Japanese Phase 3 study, 0% mortality was reported over the 30 ...
with royalties in the low double digits on net sales of Beyonttra in Japan "There is significant need for new treatment options for ATTR-CM, a progressive, fatal disease, worldwide. This latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback